To assess potential pharmacokinetic (PK) interactions between atazanavir (ATV, 300 mg, once daily) and lopinavir (LPV, 400 mg, twice daily), both boosted by ritonavir (RTV, 100 mg).
Design
Two-parallel groups, addition of LPV in patients receiving ATV (n=6), and addition of ATV in patients receiving LPV (n=7), with before/after comparisons.
Methods
Each group had two complete PK profiles before and 2 weeks after the addition of the second protease inhibitor (PI). Total plasma concentrations (Ctot) were analysed by HPLC-UV and unbound plasma concentrations (Cu) and cellular concentrations (Ccell) were analysed by LC-MS/MS. Plasma and cellular PK parameters were also calculated. Unbound and cellular fractions were expressed as Cu/Ctot and Ccell/Ctot ratio. Data were analysed by paired Student t-test on log values; correlations between Ccell, Cu and Ctot were explored by log-log linear regression.
Results
Adding LPV to ATV did not influence the plasma and cellular PK parameters of ATV. Adding ATV to LPV was associated with a decrease in LPV concentrations (by 16% for area under the time-concentration curve, maximum concentration and trough concentration, NS; and by 35% for Cmin, P=0.04). The RTV PK parameters remained unmodified. The Ccell/Ctot and Cu/Ctot ratio was unaffected by the addition of the second PI and remained stable throughout dosing interval. Good correlations were observed between Ccell, Cu and Ctot for each drug. No relevant toxicity was observed.
Conclusions
Adding LPV to ATV did not influence the plasma and cellular PK parameters of ATV. Adding ATV to LPV caused a limited decrease in LPV concentrations. The clinical significance of this decrease is unknown and warrants further investigation to determine the need for tailoring LPV dosage in selected cases.
References
1.
HammerS.M., VaidaF., BennettK.K.Dual vs single protease inhibitor therapy following antiretroviral treatment failure: a randomized trial.JAMA2002; 288: 169–180.
2.
StephanC., HentigN., KourbetiI.Saquinavir drug exposure is not impaired by the boosted double protease inhibitor combination of lopinavir/ritonavir.AIDS2004; 18: 503–508.
3.
BoffitoM., KurowskiM., KruseG.Atazanavir enhances saquinavir hard-gel concentrations in a ritonavir-boosted once-daily regimen.AIDS2004; 18: 1291–1297.
4.
KashubaA.D., TierneyC., DowneyG.F.Combining fosamprenavir with lopinavir/ritonavir substantially reduces amprenavir and lopinavir exposure: ACTG protocol A5143 results.AIDS2005; 19: 145–152.
5.
JohnsonM., GrinsztejnB., RodriguezC.Atazanavir plus ritonavir or saquinavir, and lopinavir/ritonavir in patients experiencing multiple virological failures.AIDS2005; 19: 685–694.
6.
DamE., RochasS., FaudonJ.L.Synergistic activity of lopinavir and saquinavir on protease inhibitor resistant HIV-1.11th Conference on Retroviruses and Opportunistic Infections. 8–11 February 2004, San Francisco, USA. Abstract 622.
7.
TaburetA.M., PikettyC., ChazallonC.Interactions between atazanavir-ritonavir and tenofovir in heavily pretreated human immunodeficiency virus-infected patientsAntimicrobial Agents Chemother2004; 48: 2091–2096.
8.
LeithJ., WalmsleyS., KatlamaC.Pharmacokinetics and safety of tipranavir/ritonavir (TPV/r) alone or in combination with saquinavir (SQV), amprenavir (APV), or lopinavir (LPV): interim analysis of BI1182.51.5th International Workshop on Clinical Pharmacology of HIV Therapy. 11–13 March 2004, Rome, Italy. Abstract 34.
9.
BoffitoM., MaitlandD., SamarasingheY., PozniakA.The pharmacokinetics of HIV protease inhibitor combinations.Curr Opin Infect Dis2005; 18: 1–7.
10.
KempfD.J., MarshK.C., KumarG.Pharmacokinetic enhancement of inhibitors of the human immunodeficiency virus protease by coadministration with ritonavir.Antimicrobial Agents Chemother1997; 41: 654–660.
11.
LangmannP., ZillyM., WinzerR.Efficacy and safety of ATV in combination with LPV/r. International Workshop on Clinical Pharmacology of HIV Therapy, 28–30 April 2005, Quebec, Canada. Abstract 56.
12.
AzuajeC., LopezR.M., RiberaE.Pharmacokinetics and safety of a double boosting regimen of atazanavit (ATZ). plus lopinaivr (LPV), plus minidose ritonavir in multidrug-treated HIV-infected patients.3rd European HIV Drug Resistance Workshop, 4–7 April 2005, Athens, Greece. Abstract 51.
13.
WinstonA., BlochM., CarrA.Atazanavir trough plasma concentration monitoring in a cohort of HIV-1-positive individuals receiving highly active antiretroviral therapy.J Antimicrob Chemother2005; 56: 380–387.
14.
ArmbrusterC., VorbachH., SteindlF., El MenyawiI.Intracellular concentration of the HIV protease inhibitors indinavir and saquinavir in human endothelial cells.J Antimicrob Chemother2001; 47: 487–490.
15.
BilelloJ.A., BilelloP.A., StellrechtK.Human serum alpha 1 acid glycoprotein reduces uptake, intracellular concentration, and antiviral activity of A-80987, an inhibitor of the human immunodeficiency virus type 1 protease.Antimicrob Agents Chemother1996; 40: 1491–1497.
16.
CrommentuynK.M., MulderJ.W., MairuhuA.T.The plasma and intracellular steady-state pharmacokinetics of lopinavir/ritonavir in HIV-1-infected patients.Antivir Ther2004; 9: 779–785.
17.
BruguerolleB.Chronopharmacokinetics. Current status.Clinical Pharmacokinet1998; 35: 83–94.
18.
ColomboS., GuignardN., MarzoliniC., TelentiA., BiollazJ., DecosterdL.A.Determination of the new HIV-protease inhibitor atazanavir by liquid chromatography after solid-phase extraction.J Chromatogr B Analyt Technol Biomed Life Sci2004; 810: 25–34.
19.
MarzoliniC., BeguinA., TelentiA.Determination of lopinavir and nevirapine by high-performance liquid chromatography after solid-phase extraction: application for the assessment of their transplacental passage at delivery.J Chromatogr B Analyt Technol Biomed Life Sci2002; 774: 127–140.
20.
ColomboS., BeguinA., TelentiA.Intracellular measurements of the anti-HIV drugs indinavir, amprenavir, saquinavir, ritonavir, nelfinavir, lopinavir, efavirenz, and nevirapine in peripheral blood mononuclear cells by liquid chromatography coupled to tandem mass spectrometry.J Chromatogr B Analyt Technol Biomed Life Sci2005; 819: 259–276.
21.
Food and Drug Administration.Guidance for Industry. In vivo drug metabolism/drug interaction studie -study design, data analysis, and recommendations for dosing and labeling;1999 [cited 26 Jan 2006]. Available from http://www.fda.gov/cber/gdlns/metabol.htm.
22.
PerloffE.S., DuanS.X., SkolnikP.R., GreenblattD.J., von MoltkeL.L.Atazanavir: effects on P-glycoprotein transport and CYP3A metabolism in vitro.Drug Metab Dispos2005; 33: 764–770.
23.
Panel on Clinical Practices for Treatment of HIV infection, Department of Health and Human Services.Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents;2005 [cited 26 Jan 2006] Available from http://aidsinfo.nih.gov/guidelines/adult/AA_040705.pdf.
24.
BoffitoM., BackD.J., BlaschkeT.F.Protein binding in antiretroviral therapies.AIDS Res Hum Retroviruses2003; 19: 825–835.
25.
BilelloJ.A., DrusanoG.L.Relevance of plasma protein binding to antiviral activity and clinical efficacy of inhibitors of human immunodeficiency virus protease.J Infect Dis1996; 173: 1524–1526.
SmithC.M., FaucetteS.R., WangH., LeCluyseE.L.Modulation of UDPglucuronosyltransferase 1A1 in primary human hepatocytes by prototypical inducers.J Biochem Mol Toxicol2005; 19: 96–108.
28.
LeeG.A., RaoM.N., GrunfeldC.The effects of HIV protease inhibitors on carbohydrate and lipid metabolism.Curr Infect Dis Rep2004; 6: 471–482.
29.
PurnellJ.Q., ZambonA., KnoppR.H.Effect of ritonavir on lipids and post-heparin lipase activities in normal subjects.AIDS2000; 14: 51–57.
30.
BeckerS., FisherA., FlexnerC.Pharmacokinetic parameters of protease inhibitors and the Cmin/IC50 ratio: call for consensus.J Acquir Immune Defic Synd2001; 27: 210–211.
